SharpSense™ technology harnesses the power of extra discriminators to confirm or reject detections - improving accuracy.1,2
SharpSense technology is designed with more discriminators, improving specificity while maintaining a high relative sensitivity, to give you actionable information you can use to confidently diagnose bradycardia, pause and AF.1
Actively reviews the previous 30 seconds for the presence of P-waves to discern an AF episode.
Relative Sensitivity: 97.2%1
Dynamically evaluates multiple R-waves and P-waves to create customized thresholds to detect true bradycardia episodes.
Relative Sensitivity: 98.6%1
Analyzes P-wave and R-wave characteristics during the previous 6 seconds, based on customized secondary thresholds, to detect true pause episodes.
Relative Sensitivity: 98.1%1
The Confirm Rx ICM device continuously monitors patient rhythm for up to 2 years (730 days).6
Median time to detect an AF episode in patients with Cryptogenic Stroke when using an implantable loop recorder.4†
Median time for diagnosis in patients with Unexplained Syncope when using an implantable loop recorder.5
Confirm Rx ICM offers up to 730 days of continuous heart monitoring — providing ample time to diagnose the most difficult-to-detect arrhythmias.6
*Determined by evaluation of real-world episodes in previously identified devices, using SharpSense Technology
† This information was not collected with the Confirm Rx ICM Device and is meant to provide information to the broader class of devices.
You are about to enter an Abbott country- or region-specific website.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions
Do you wish to continue and enter this website?